Browse EyeWorld Weekly ophthalmology news on EyeWorld.org. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.

EyeWorld Weekly, July 7, 2023

➤ Enrollment complete in MIGS pivotal trial ➤ Acquisition of dry eye drop ➤ Two-year results post-cilio-scleral glaucoma procedure ➤ Positive topline results from Phase 2 study of retinitis pigmentosa treatment ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, July 7, 2023

EyeWorld Weekly, June 30, 2023

➤ Study evaluates safety of office-based lens surgery ➤ FDA issues response to BLA for 8 mg aflibercept ➤ Pre-clinical data for non-viral gene therapy ➤ Non-human primate study of dry AMD therapy ➤ Expanded insurance coverage for MIGS procedures ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, June 30, 2023

EyeWorld Weekly, June 23, 2023

➤ Positive topline results in Phase 3 clinical trial for allergic conjunctivitis treatment ➤ Phase 1b topline data on investigational dry eye drop ➤ First patients dosed in Phase 1b/2 trial for Wnt agonist antibody ➤ Study: U.S. prevalence of diabetic retinopathy ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, June 23, 2023

EyeWorld Weekly, June 16, 2023

➤ Cataract surgery survey results ➤ FDA approves first non-degradable, synthetic tissue for ophthalmic surgery ➤ New cyclosporine ophthalmic solution approved for dry eye ➤ Results from Phase 2b study of drug-eluting contact lens ➤ 12-month topline data for intravitreal implant in wet AMD trial ➤ AAV capsid licensed for ocular gene therapy indication ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, June 16, 2023

EyeWorld Weekly, June 9, 2023

➤ Results from Phase 2a study evaluating glaucoma drop ➤ Enrollment complete for epi-on crosslinking trial ➤ Phase 2 clinical trial begins for investigational dry eye drop ➤ Enrollment complete for Phase 2 study to evaluate diabetic retinopathy treatment ➤ Phase 2b trial for wet AMD treatment begins enrollment ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, June 9, 2023

EyeWorld Weekly, June 2, 2023

➤ Phase 2 trial with experimental geographic atrophy treatment shows preservation of visual function ➤ AI-enabled screening system receives FDA clearance ➤ Enrollment complete for study evaluating investigational first-line therapy for DME ➤ Updates from two retinitis pigmentosa trials ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, June 2, 2023

EyeWorld Weekly, May 26, 2023

➤ FDA approves dry eye drop targeting tear evaporation ➤ Topline results from Phase 3 trial of eye drops for DME ➤ Investigational intravitreal gene therapy program introduced for geographic atrophy ➤ Phase 1 study for periocular drug for wet AMD and DME begins ➤ Commercial rights for uveitis treatment acquired ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, May 26, 2023

EyeWorld Weekly, May 19, 2023

➤ Researchers discover new class of drugs that could treat retinal dystrophies ➤ Enrollment complete in Phase 1/2a study using novel dry eye treatment approach ➤ NDA submitted to FDA for investigational inflammation and pain treatment ➤ Study: first-in-human gene therapy trial for achromatopsia ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, May 19, 2023

EyeWorld Weekly, May 12, 2023

➤ FDA approves ophthalmic spray for mydriasis ➤ FDA accepts NDA for travoprost intraocular implant ➤ FDA accepts supplemental BLA for treatment for macular edema ➤ FDA 510(k) clearance granted to green pattern laser photocoagulator ➤ NDA submitted for pain and inflammation nanoemulsion ➤ Positive clinical results from IOP-monitoring contact lens ➤ Study provides real-world data comparing MIGS using IRIS Registry ➤ FDA approves IOL positioning system ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, May 12, 2023

EyeWorld Weekly, May 5, 2023

➤ Topline data from Phase 3 presbyopia drop trial ➤ Femtosecond laser for LASIK receives FDA clearance ➤ Enrollment complete for hydrophobic trifocal IOL trial ➤ Early results from clinical trial for dry eye therapy ➤ FDA clears IND application for clinical trial of therapy for X-linked retinoschisis ➤ Innovations in capsulotomy creation device ➤ Company acquisition news ➤ ASCRS news and events

Comments Off on EyeWorld Weekly, May 5, 2023